reports
Abcam: 1 director
A director at Abcam bought 15,000 shares at 15.410USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
ABCAM sees an upgrade to Slightly Positive due to a better fundamental...
The general evaluation of ABCAM (GB), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 18, 2022, the closing price was GBp 1,359.00...
Abcam Plc Results for the 12- and 18-month periods ended 31 December 2...
Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021 Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The Group’s accounting reference date changed ...
29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually R...
29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December1, therefore these interim financial statements report on both a six- and 12-month per...
Abcam to Acquire BioVision for $340 million
Abcam to Acquire BioVision for $340 million CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). Transaction highlights BioVision is a fast-growing innovator and distributor of life science research tools to biopharma, diagnostic ...
Abcam and MEDx extend precision medicine strategic partnership
Abcam and MEDx extend precision medicine strategic partnership Building on existing three-year collaborationFocusing on co-development of companion and in vitro diagnostic kits to support demand in China CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-...
Abcam Wins Industry Awards from CiteAb
Abcam Wins Industry Awards from CiteAb CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘ and the Company was recognized as ‘. On receiving her award, Dr Alejandra Solache, SVP of R&D, Abcam, said: “Thank you very much to the team at for this award. I am passionate about promoting the importance of reagent quality across the life science sector. It is an honor to receive this award and I would ...
8.3% constant currency revenue growth in H1 as customers gradually ret...
8.3% constant currency revenue growth in H1 as customers gradually return to labs CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 December 2020 (“H1 2021”). SUMMARY PERFORMANCE Reported Adjusted1 H1 2021£mH1 2020£m H1 2021£mH1 2020£mRevenue147.5138.2 147.5138.2Gross profit margin, %70.9%69.7% 70.9%69.7%Operating profit15.526.6 23.633.4Profit Before Tax (PBT)13.826.0 21...
Abcam Expands Presence in China to Support Increased Demand of BioPhar...
Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector Scaling up R&D, manufacturing and commercial capabilities in Shanghai and Hangzhou Investing in state-of-the-art facilities and equipment to support research, diagnostic and clinical applications CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service, logistics and manuf...
Abcam to Report Interim Results on Monday, March 8, 2021
Abcam to Report Interim Results on Monday, March 8, 2021 CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021. Following the announcement, the Company will host a live teleconference and webcast at 2:00 p.m. GMT (9:00 a.m. EST) that same day (details below). To access the webcast, please use the following link: ...
Abcam to present at the 2021 SVB Leerink Global Healthcare Conference
Abcam to present at the 2021 SVB Leerink Global Healthcare Conference CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8.00 EST / 13.00 GMT. A live webcast of the presentation can be accessed via the IR Calendar page of Abcam’s Investor Relations website at . Contact: James Staveley, VP, Investor Relations+44 (0) 1223 392 948 About Abcam plcAs an innovator in reagents and tools, Abcam'...
Abcam Plc Appointment of Non-Executive Directors
Abcam Plc Appointment of Non-Executive Directors CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. Both Bessie and Mark bring extensive and complementary executive and non-executive experience to the Board of Abcam. Based in China, Bessie Lee is the Chief Executive Officer of Withinlink, a China-based venture capital firm and start-up incubator focus...
Abcam plc Half Year Trading Update
Abcam plc Half Year Trading Update Abcam returns to growth in first half with over 8% increase in constant currency revenue CAMBRIDGE, United Kingdom, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, announces the following unaudited trading update ahead of reporting its results on 8 March 2021 for the six months ended 31 December 2020. Overall, we expect to report total first half revenue of £147.5 million (H1 2020: £138.2 million), representing growth of 8.3% on a constant currency basis and ...
Abcam plc: Annual Report, Impact Report and Notice of AGM
Abcam plc: Annual Report, Impact Report and Notice of AGM CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 September 2020 of its final results for the year ended 30 June 2020, the Abcam plc Annual Report and Accounts 2020 (the “Annual Report”) have been published today and are available on the Abcam plc website at . A copy of the Annual Report has been submitted to the National Storage Mechanism and will shortly be available for inspection...
Abcam plc: Consultation on 2020 LTIP Awards
Abcam plc: Consultation on 2020 LTIP Awards CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation with shareholders on the Group’s overall LTIP structure and performance framework, including proposed changes for this year’s awards, it has determined to retain the existing LTIP metrics and targets contained in Abcam’s current Remuneration Policy, as approved by shareholders in 2018. Furthermore, Abcam intends to continue consulting with sharehold...
Abcam Announces Closing of Offering
Abcam Announces Closing of Offering THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) ("Abcam"), a global leader in the supply of life science research tools, announces today the closing of its offering of an aggregate of 10,287,000 American Depositary Shares ("ADSs") representing 10...
Abcam Announces Pricing of Offering on NASDAQ
Abcam Announces Pricing of Offering on NASDAQ This Announcement Contains Inside Information for the Purposes of Article 7 of Regulation (EU) No 596/2014 LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (“Abcam”), a global leader in the supply of life science research tools, announces today the pricing of its offering of 8,945,218 American Depositary Shares (“ADSs”), representing an aggregate of 8,945,218 ordinary shares, at a price of $17.50 per ADS, for aggregate proceeds of approximately $156.5 million, before deducting underwriting discounts and commissions. Each ADS of...
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Bottoms-up view on developed int'l, part two Big Picture: Our outlook remains neutral on the MSCI ACWI ex-U.S. index (when priced in local currency) while horizontal consolidation continues. On the other hand, we are negative on broad global ex-U.S. markets when priced in USD... see charts below. In today's report we take a bottoms-up approach to developed ex-U.S. equities, highlighting stocks that present attractive buy opportunities at current levels. Specifically we present actionable stocks...
IPN IPSEN SA
MTX MTU AERO ENGINES AG
HO THALES SA
LONN LONZA GROUP AG
QIA QIAGEN NV
AWC ALUMINA LIMITED
SGC STAGECOACH GROUP PLC
FAGR FAGRON SA
CPX. CAPITAL POWER CORPORATION
MX. METHANEX CORPORATION
WKL WOLTERS KLUWER NV
VIRP VIRBAC SA
MRK MERCK KGAA
AHT ASHTEAD GROUP PLC
MNDI MONDI PLC
AIR AIRBUS SE
ABC ABCAM PLC
AMP AMPLIFON S.P.A.
AFN AG GROWTH INTERNATIONAL
KXS KINAXIS INC.
INRN INTERROLL HOLDING AG
SAAB B SAAB AB CLASS B
3407 ASAHI KASEI CORPORATION
4704 TREND MICRO INCORPORATED
4519 CHUGAI PHARMACEUTICAL CO. LTD.
6787 MEIKO ELECTRONICS CO. LTD.
006400 SAMSUNG SDI CO. LTD
REG1V REVENIO GROUP OYJ
SFZN SIEGFRIED HOLDING AG
ANOD B ADDNODE GROUP
6670 MCJ
5288 ASIA PILE HOLDINGS
XRO XERO LIMITED
HNSA HANSA BIOPHARMA AB
AMS AMADEUS IT GROUP SA CLASS A
020150 ILJIN MATERIALS
NMC NMC HEALTH PLC
178920 SKC KOLON PI
CRDA CRODA INTERNATIONAL PLC
4348 INFOCOM CORP
5331 NORITAKE CO. LTD.
8056 NIHON UNISYS LTD.
CDA CODAN
SIS SAVARIA CORP.
ENC ENCE ENERGIA Y CELULOSA SA
INX IMCD N.V.
ARV ARVIDA GROUP
4503 ASTELLAS PHARMA INC.
AZN ASTRAZENECA PLC
OTEX OPEN TEXT CORPORATION
SANT S&T AG
SCH SCHIBSTED ASA CLASS A
4189 KH NEOCHEM CO. LTD.
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Se...
RYM RYMAN HEALTHCARE LTD.
EVT EVOTEC SE
10BC NASPERS LIMITED CLASS N
EL ESSILORLUXOTTICA SA
PSON PEARSON PLC
WKL WOLTERS KLUWER NV
DPH DECHRA PHARMACEUTICALS PLC
MRK MERCK KGAA
SVW SEVEN GROUP HOLDINGS LIMITED
E3G1 EVOLUTION GAMING GROUP AB
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
ORP ORPEA SA
ABC ABCAM PLC
LUN H. LUNDBECK A/S
DMGT DAILY MAIL & GENERAL TRUST PLC CLASS A
CEVI CELLAVISION AB
SANOFI SANOFI INDIA
PFIZER PFIZER
ABBOTINDIA ABBOTT INDIA
EBO EBOS GROUP
REA REA GROUP LTD
COH COCHLEAR LIMITED
4751 CYBERAGENT INC.
7716 NAKANISHI
6869 SYSMEX CORPORATION
TECN TECAN GROUP AG
STMN STRAUMANN HOLDING AG
T39 SINGAPORE PRESS HOLDINGS LIMITED
ENT ENTAIN PLC
3151 VITAL KSK HOLDINGS
LIFCO B LIFCO AB CLASS B
DIM SARTORIUS STEDIM BIOTECH SA
IPCALAB IPCA LABORATORIES LIMITED
2784 ALFRESA HOLDINGS CORPORATION
2371 KAKAKU.COM INC.
7701 SHIMADZU CORPORATION
SHL SONIC HEALTHCARE LIMITED
9987 SUZUKEN CO. LTD.
DIA DIASORIN S.P.A.
3665 ENIGMO
SPI SPIRE HEALTHCARE GROUP PLC
AZN ASTRAZENECA PLC
TSGI STARS GROUP INC
VIFN VIFOR PHARMA AG
AUP AURORA PROPERTY BUY-WRITE INCOME TRUST
SECT B SECTRA AB B
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
The U.S. has continued to separate itself from broad emerging market and developed international indexes. Thankfully, one positive is that MSCI EM and MSCI EAFE have been able to stabilize from a price perspective despite relative strength weakness vs. MSCI ACWI... see charts below. In today's report we scour the globe for attractive investments in an environment where selectivity is key. • Emerging markets. There is still not much to like about broad EM as the MSCI Emerging Markets index ...
IPN IPSEN SA
EQNR EQUINOR ASA
INFY INFOSYS LIMITED
J2B EXPERIAN PLC
LONN LONZA GROUP AG
ERF ENERPLUS CORPORATION
CLIN CLINIGEN GROUP PLC
HUSKF HUSKY ENERGY INC.
AIA AUCKLAND INTERNATIONAL AIRPORT LIMITED
PMO PREMIER OIL PLC
OXB OXFORD BIOMEDICA PLC
3JDA RIGHTMOVE PLC
NOVO B NOVO NORDISK A/S CLASS B
ALA ALTAGAS LTD.
SOBI SWEDISH ORPHAN BIOVITRUM AB
CJ5A CGI
CPU COMPUTERSHARE LIMITED
CAP CAPGEMINI SE
ABC ABCAM PLC
PXT PAREX RESOURCES INC.
FAE FAES FARMA S.A.
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
KEY. KEYERA CORP.
GUD KNIGHT THERAPEUTICS
BPT BEACH ENERGY LIMITED
4559 ZERIA PHARMACEUTICAL CO. LTD.
COH COCHLEAR LIMITED
FSX FUTURE CORP
9682 DTS CORP.
4812 INFORMATION SERVICES INTERNATIONAL-DENTSU LTD.
6869 SYSMEX CORPORATION
STMN STRAUMANN HOLDING AG
2427 OUTSOURCING INC.
SKIS B SKISTAR AB
NAN NANOSONICS
FLRY3 FLEURY SA
NMC NMC HEALTH PLC
DIM SARTORIUS STEDIM BIOTECH SA
FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED
7730 MANI
WOR WORLEY LIMITED
7459 MEDIPAL HOLDINGS CORPORATION
9987 SUZUKEN CO. LTD.
8129 TOHO HOLDINGS CO. LTD.
7747 ASAHI INTECC CO. LTD.
2412 BENEFIT ONE INC.
3769 GMO PAYMENT GATEWAY INC.
5020 ENEOS HOLDINGS INC.
DHG DALATA HOTEL GROUP PLC
4503 ASTELLAS PHARMA INC.
POX PANDOX AB CLASS B
AZN ASTRAZENECA PLC
VIFN VIFOR PHARMA AG
145720 DENTIUM
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.